Share Prices & Company Research

Stockbroking

Oncimmune Holdings

Current Price 50.60p Bid 50.00p Ask 55.00p Change -10.26%
Last Updated: 26/02/2020 10:54. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Oncimmune Holdings plc is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT tests for liver and ovarian cancer are in development.

Financial Highlights Year Ended 31/05/2019

Turnover
£0.17m
Operating Profit
£-8.59m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-4.16

Key Personnel

Dr Adam Mark Hill
Chief Executive Officer
Frank Matthew Sunderland Hall
Chief Financial Officer
Geoffrey Neil Hamilton-Fairley
Executive Vice Chairman
Meinhard Folkert Schmidt
Non-Executive Chairman
Timothy Brian Bunting
Non-Executive Dep Chairman
Andrew Vaughan Unitt
Non-Executive Director
Dr Cheung To
Non-Executive Director
Richard Simon Sharp
Non-Executive Director
Carsten Schroeder
Non-Executive Director
Dr Annalisa Mary Jenkins
Non-Executive Director
Julian Clement Hirst
Non-Executive Director

Stock Details

EPIC
ONC
ISIN
GB00BYQ94H38
Shares in Issue
63,250,217
Market cap
£34.16m
Sector

Analyst Views (1)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
100.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
52.50p
Bid Price
50.00p
Ask Price
55.00p
Volume
33211
Change Today
-6.00p
% Change Today
-10.26%
Open
56.00p
Previous Close
58.50p
Intraday High
56.00p
Intraday Low
50.60p
52 Week High
115.00p
52 Week Low
31.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Oncimmune Holdings Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2019
31 May 2018
Tangible Assets
0.4
0.2
Intangible Assets & Goodwill
3.0
0.7
Investments & Other Non-Current Assets
0.0
0.0
Total Non-Current Assets
3.4
0.9
Inventory
0.3
0.3
Trade & Receivables
0.4
0.3
Cash & Receivables
5.4
13.0
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
9.4
14.4

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2019
31 May 2018
Short Term Liabilities
1.1
0.9
Long Term Liabilities
0.5
0.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1.6
0.9

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2019
31 May 2018
Net Assets
7.9
13.6

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2019
31 May 2018
Share Capital
0.6
0.6
Minority Interests
0.0
0.0
Retained Earnings
-57.4
-49.3
Share Premium Account
31.4
31.0
Other Equity
33.2
31.3
Total Equity
7.9
13.6

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2019
31 May 2018
Cashflow from Operating Activities
-7.4
-6.1
Cashflow Before Financing
-7.5
-6.4
Increase / Decrease in Cash
-7.6
7.9

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2019
31 May 2018
Turnover
0.2
0.2
Cost of Sales
1.0
0.9
Gross Profit
-0.9
-0.7
Operating Profit
-8.6
-6.4
Pre-Tax Profit
-8.6
-6.3
Profit / Loss for the Year
-8.0
-6.3
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.